The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory agencies to drugs in development for the treatment of rare diseases, and where the pharmaceutical company will profit…
News
The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. The company’s Phase 2/3 DELIVERS clinical trial (NCT03154333) is currently recruiting participants. CCP-020 is a small molecule, engineered to…
News
FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder
The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
Recent Posts
- Double dose of Vyjuvek safely heals extensive wounds in woman with RDEB
- Searching for a faith community that fulfills our family’s needs
- Repurposing existing medicines may offer faster route to new EB treatment
- Approved psoriasis drug apremilast to be tested in severe EBS patients
- An unbreakable sibling bond that surprisingly resulted from EB